| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company's XTRAC capability to address the condition
HORSHAM, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces a groundbreaking clinical case study published in Case Reports in Oncology. The study reports the successful use of 308-nm excimer laser to treat a rare and under-recognized form of cutaneous T-cell lymphoma, mycosis fungoides (MF) through a subtype called poikilodermatous mycosis fungiodes (pMF).
Led by dermatology researchers at Tohoku University Graduate School of Medicine, the newly published, peer reviewed study (Case Rep Oncol 2025;18:325–329) represents a first-of-its-kind English-language report validating excimer laser therapy as a safe and effective option for this difficult-to-treat condition.
Posted In: SSKN
